This article is a collaboration between MedPage Today and:
Clinical trials of pancreatic cancer fail to include and report on representative proportions of non-white patients at every study phase, researchers suggested.
This discrepancy is troubling in that certain racial and ethnic minorities get pancreatic cancer more often, are diagnosed at a younger age, and die sooner, noted Kelly Herremans, MD, of the University of Florida College of Medicine in Gainesville. Currently there s a heightened awareness of racial and ethnic disparities in society, particularly in healthcare, Herremans said during a press briefing held in advance of the annual Digestive Disease Week meeting.
Dr Maha Hussain at the recent virtual ASCO Meeting. Credit: ASCO
Second look analysing prostate cancer study data reaps new rewards
Two studies unveiled at last month’s virtual Genitourinary Cancers Symposium, organised by the American Society of Clinical Oncology, will have implications for both the treatment of prostate cancer and the provision of screening,
Peter Doyle reports
In men with non-metastatic castration-resistant prostate cancer (nmCRPC) and rapidly rising prostate specific antigen (PSA) treated with androgen deprivation therapy (ADT) plus enzalutamide (ENZA), there was a close relationship between the degree of PSA decline and survival outcomes, according to a newly published post-hoc analysis of the PROSPER trial.
SHARE
ASCO GU 2021: Association of Reductions in PSA Screening Across States with Increased Metastatic Prostate Cancer in the United States
Published 13 February 2021
(UroToday.com) Prostate cancer screening using prostate-specific antigen (PSA) testing has been controversial since shortly after its introduction in large part due to concerns of over-diagnosis and over-treatment, with the associated morbidity. Thus, despite improvements in prostate cancer-related metastasis and mortality demonstrated in the European Randomized Study of Screening for Prostate Cancer (ERSPC) randomized trial from Europe, PSA screening has remained contentious. In both 2008 and 2012, the US Preventive Services Task Force (USPSTF) did not recommend PSA screening. Some have attributed increased rates of metastatic prostate cancer in the US to reductions in PSA screening as a result of these recommendations from the USPSTF. To test this hypothesis, in the Poster Highlights: Prostate Cancer - Localized
Drop in PSA Screening, Increase in Metastatic Prostate Cancers medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.